Grand Decade and existing investor Boehringer Ingelheim Venture Fund helped supply $38.2m for the mRNA immunotherapy developer and Vrije Universiteit Brussel spinout.

Chalmers Ventures portfolio company Biofrigas has set out plans for a $1.7m IPO but has already issued around $1.2m to existing connections.

Wandelbots, which came out of Technical University of Dresden research, secured the funding as it publicly launched its robotics training software tool.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Continental Grain invested in a series D round that boosted the RNA technology provider's overall funding to $214m as it allocates more resources to vaccine work.

Returning investors Axel Springer and Purplebricks combined to invest $45.2m in the online real estate brokerage that will fund hiring and product development.

Next47 and M12 took part in Wandelbots' latest round, which came as it publicly launched its robotics training software tool.

The Eli Lilly and Genmab-backed RNA drug developer is now valued at nearly $1.5bn following a decision to refocus on a coronavirus vaccine.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The Eli Lilly and Genmab-backed RNA drug developer is now valued at nearly $1.5bn following a decision to refocus on a coronavirus vaccine.